Detalhe da pesquisa
1.
Early antibody therapy can induce long-lasting immunity to SHIV.
Nature
; 543(7646): 559-563, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28289286
2.
Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.
Proc Natl Acad Sci U S A
; 117(36): 22436-22442, 2020 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32820072
3.
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
Nature
; 503(7475): 277-80, 2013 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24172896
4.
Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.
Proc Natl Acad Sci U S A
; 109(48): 19769-74, 2012 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-23129652
5.
Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein.
J Virol
; 87(15): 8798-804, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23720719
6.
Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.
J Virol
; 85(20): 10617-26, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21813599
7.
Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia.
J Exp Med
; 218(1)2021 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966579
8.
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.
J Exp Med
; 211(10): 2061-74, 2014 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25155019
9.
Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques.
J Virol
; 81(19): 10669-79, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17626082
10.
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
Proc Natl Acad Sci U S A
; 100(25): 15131-6, 2003 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-14627745
11.
Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic.
J Virol
; 78(10): 5513-9, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15113931
12.
Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic.
Proc Natl Acad Sci U S A
; 99(21): 13813-8, 2002 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12370415
13.
Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.
J Virol
; 77(20): 10829-40, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14512533
14.
Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses.
Proc Natl Acad Sci U S A
; 101(33): 12324-9, 2004 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-15297611
15.
Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages.
J Virol
; 77(24): 13042-52, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14645561